



亞獅康股份有限公司

終止有價證券於財團法人中華民國證券櫃檯買賣中心交易

股份轉換至那斯達克(NASDAQ)上市之美國存託憑證(ADS)

轉換辦法暨投資人問答

亞獅康股份有限公司(ASLAN Pharmaceuticals Limited，股票代碼 6497)（下稱「本公司」或「亞獅康」）於民國 109 年 7 月 16 日接獲財團法人中華民國證券櫃檯買賣中心（下稱「櫃買中心」）正式通知，因不符合財團法人中華民國證券櫃檯買賣中心證券商營業處所買賣有價證券業務規則第十二條之二，預計將於民國 109 年 8 月 25 日起終止有價證券櫃檯買賣。

本公司股票將持續以美國存託憑證 American Depositary Shares (ADS)形式於美國那斯達克證券交易所掛牌。本公司有價證券終止櫃檯買賣並不會影響本公司之有價證券持續於那斯達克證券交易所掛牌及交易，且美國那斯達克將成為本公司有價證券之主要交易市場，而原本持有美國存託憑證之股東對此無須採取任何行動。

本公司將協助台灣股東進行股份轉換為美國存託憑證至那斯達克證券交易所持續存續及交易。本公司之股東並無義務參與本次轉換，若無意願轉換之股東則可以在終止有價證券櫃檯買賣日前將所持股份於台灣市場出售，或持續持有本公司開曼股份。特別注意，一旦本公司有價證券終止櫃檯買賣，本公司有價證券唯一公開交易市場將會是透過美國存託憑證於那斯達克證券交易所進行交易。

以下針對股票轉換辦法及股東常見問題說明：

1. 何謂美國存託憑證(ADS)?

美國存託憑證係外國公司於美國證券市場交易股票的一種形式。大多數的外國公司在美國證券市場透過存託憑證形式進行交易並提升國際知名度。就亞獅康案例而言，我們的存託機構係為世界領先銀行之一的摩根大通銀行 J.P. Morgan Chase Bank, N.A.(J.P. Morgan)，目前每單位美國存託憑證表彰本公司普通股 5 股(此所稱普通股與目前在台灣證券櫃檯買賣中心上櫃之股份類別相同)。本公司之美國存託憑證在那斯達克證券交易所掛牌之股票代碼為 "ASLN"。

除受到一些豁免和限制之約束，本公司美國存託憑證於那斯達克上市應遵循之法規以及應公告事項之縝密性要求，與在美國當地第一上市的公司標準一致。自亞獅康



於 2018 年 5 月在那斯達克上市以來均符合美國當地證管法令規範。藉由美國存託憑證在美國證券市場的公開發行，亞獅康在美國證券市場獲得眾多且對於生技新藥極具經驗的投資人基礎優勢，同時也為外國生技新藥公司股票在美國證券市場展開了較具高度的流通性。

2. 股東是否能將台灣的股票轉換為美國存託憑證？

本公司認為將台灣的股票轉換為美國存託憑證將可能達到股東們的最佳利益，係因美國存託憑證的歷史價格及交易流通性遠高於本公司股票在櫃買中心交易。本公司有價證券於台灣停止公開發行後，才能依據本投資人問答概述的轉換辦法及流程，協助股東將所持有之本公司股份轉換為美國存託憑證。且前述於台灣停止公開發行，仍需取得金融監督管理委員會證券期貨局(下稱「金管會證期局」)之核准。本公司預定於民國 109 年 9 月 4 日之股東臨時會上決議停止於台灣公開發行案並提請金管會證期局停止本公司於台灣公開發行，其裁量權之行使將考量股東會投票結果，故本公司懇請股東積極參與民國 109 年 9 月 4 日之股東臨時會之相關重要決議。

假使本公司在台灣仍是公開發行公司，則股東的股份將無法轉換為美國存託憑證，亦無法於民國 109 年 8 月 25 日終止有價證券櫃檯買賣後，在任何公開證券市場上進行交易。

3. 誰可以將其股票轉換為美國存託憑證？

本公司股票於證券櫃檯買賣之最後交易日為 109 年 8 月 24 日，109 年 8 月 25 日為有價證券終止櫃檯買賣日，即日起，所有股票將無法於公開市場買賣。

依本公司董事會決議通過之股份轉換辦法，所有於最後交易日 109 年 8 月 24 日前(含當日)取得本公司股票之股東，將有權將其所持股份依本公司美國存託憑證表彰比率(每單位美國存託憑證表彰本公司普通股 5 股)、如數轉換為美國存託憑證。

(注意: 未達 5 股之畸零股普通股將不足轉換 1 股美國存託憑證)

為避免產生爭議，本公司董事會已決議任何於民國 109 年 8 月 25 日後，私下過戶轉讓之股份均不具有轉換美國存託憑證之權利。

4. 何時能開始申請將其股票轉換為美國存託憑證？

本公司股票將於民國 109 年 8 月 25 日終止有價證券櫃檯買賣日(含當日)起，接受申請轉換。有意願將其所持有之本公司股份轉換為美國存託憑證，且符合資格之股東必須於民國 109 年 9 月 25 日前提提交申請，以適用本轉換辦法所述流程。



您可從本公司網站股東服務專區下載美國存託憑證轉換申請表格或洽當地執行單位群益金鼎證券股份有限公司（下稱「群益證券」）親自索取申請表格（請參閱第 7 點）開始轉換文件準備。申請表格需待本公司於台灣停止公開發行後才能生效。本公司預估此過程大約需 1 至 2 個月完成。

5. 是否有任何轉換時間限制？

本公司將於民國 109 年 8 月 25 日(含當日)起受理股東轉換申請，且首批美國存託憑證轉換申請截止日為民國 109 年 9 月 25 日。任何於 109 年 9 月 25 日後收到的股東申請可能無法以本轉換辦法所述流程辦理。

6. 股東必須準備什麼先決條件才能進行股份轉換？

為了順利取得美國存託憑證，您必須先擁有可供交易之美國證券戶或透過國內券商開立的複委託帳戶。若您並無具備前述之條件，您將無法將亞獅康股票轉換為亞獅康美國存託憑證。

7. 相關程序和申請表單為何？

您必須先與您的開戶證券經紀商聯繫以指示將您的無實體股票自集中保管帳戶移轉至登錄帳戶 3DP8-5555555，以供群益證券進行轉換程序。

嗣後請洽群益證券或本公司官方網站取得下列文件。文件將於民國 109 年 7 月 25 日後開放下載。（<http://aslanpharma.com/zh/investors/shareholder-services/> 投資者關係 - 股東服務專區）

- **股份轉讓書 Instrument of Transfer:**

這份文件將交付給本公司開曼登記代理人，足茲證明持有人同意將所持開曼股份透過存託機構將您持有的本公司股份轉換為美國存託憑證並予以登記在 JPMorgan Chase Bank N.A. 摩根大通名下（連同其他美國存託憑證持有人）。請與群益證券確認可供轉換之普通股數量並簽署股份轉讓書；

- **股份送達書 Letter of Transmittal:**

這份文件將交付給本公司存託機構摩根大通銀行 J.P. Morgan，來允許摩根大通銀行 J.P. Morgan 將轉換後的美國存託憑證交付給您的證券經紀商。表格內容請留下空白，確定之可轉換股數、股票編號、股票日期將由開曼/分支登記處代您確認及填寫。除股東帳戶資訊提供外，此份文件僅需您的簽字即可轉發給摩根大通銀行 J.P. Morgan 進行使用。



一旦完成上述申請表格，請於民國 109 年 9 月 25 日前盡速將正本以掛號郵寄/親送至群益證券並繳交相關費用(請參閱第 10 點)。

請注意，群益證券僅於本公司有價證券終止櫃檯買賣（即民國 109 年 8 月 25 日含當日）後開始收受辦理，群益證券有權依本公司辦法進行表單確認及檢查，以供本公司之開曼登記代理人及摩根大通銀行 J.P. Morgan 順利發行美國存託憑證。

8. 轉換程序大約多久可以完成？

如股東已備妥所有上述文件、經群益證券確認資訊無誤且相關費用如數繳付，摩根大通銀行 J.P. Morgan 於收到所有正本申請文件後將於 1 至 2 個月內完成本公司股票轉換為美國存託憑證、並撥付該美國存託憑證至您指定之美股交易帳戶之流程。惟本公司不擔保超出其控制範圍之時間表。

9. 何時可以在那斯達克市場上交易亞獅康存託憑證？

您必須指示您的證券經紀商接收本公司存託銀行 J.P. Morgan 交付美國存託憑證之指令，您的美國證券經紀人或台灣複委託證券經紀人將告知您是否有其他需求即能完成美國存託憑證撥付，隨後，您立即可以在那斯達克證券交易所進行交易。

10. 估計成本為何？

以下費用係將支付予第三方的發行費用及行政作業費，無應支付予公司之費用：

- 美國存託憑證發行費用：
每位股東均需負擔所持股份轉換至美國存託憑證之每股發行成本。每單位美國存託憑證轉換/發行成本為 5 美分(美金\$0.05 元)，此項發行成本係由摩根大通銀行 J.P. Morgan 收取，不包含其他稅捐或您所在地證券經紀人額外收取之手續費。
- 行政作業費：
每位股東均需負擔美金 20 元之行政作業費。此係一次性且將轉支付予相關第三方進行股份轉換之相關費用。



例如：您持有 1,000 股普通股股票(相當於 200 股美國存託憑證)，您需要於繳交轉換文件時同時支付共計美金\$30 元(200 股美國存託憑證*美金 0.05 元+美金 20 元)給群益金鼎指定帳戶。相關資訊將於轉換申請文件中可取得。

另，本投資人問答概述下列可能發生之其他成本僅供投資人參考(視股東/證券商情況而有所不同)：

- 開戶手續費：
如您希望開立美國股票交易帳戶可能產生開戶手續費，請洽各證券商經紀商。
- 交易活動費 (TAF) / 交易徵費：
當您買賣美國存託憑證時，您的證券商經紀商將以成交股數計算向您收受交易活動費，賣出時收取約成交金額之 0.00221%，最低收取 0.01 美元，最高美元 5.95 美元。此項費用將依據您的證券商經紀商及美國當局不定期調整。
- 美國存託憑證經紀商保管費：
買進美國存託憑證如於保管費用收取基準日時尚有持股，將會被美國保管機構收取保管費用。美國存託憑證保管費約每股 0.01 美元至 0.05 美元不等，每半年、一年或定期向持有人收取一次，具體費用取決於您的證券商經紀商。

上述費用係基於本公司製作本投資人問答時，本公司取得之信息，無法保證上述費用的準確性及完整性。

請聯繫您個人的稅務諮詢顧問以獲取有關在美國那斯達克交易所買賣美國存託憑證可能產生的各項稅務規劃建議，本公司概不提供股東個人財務規劃諮詢。

11. 如股東無意願將股票轉換為美國存託憑證之處置為何？

如您無意願轉換為美國存託憑證，您得以在民國 109 年 8 月 25 日本公司有價證券終止證券櫃檯買賣日前，於台灣公開市場將您所持有之本公司股份出售，在前述日期之後，您所持股票將無法在台灣或其他證券交易所上進行公開買賣。

然而，如您選擇不轉換或私下過戶無轉換權之股票(詳第 3 點定義)，您仍為亞獅康股份有限公司(開曼公司)之股東，仍有資格於未來參與本公司配發股息或股東大會，並依開曼群島法律程序進行私人過戶出售。如本公司於可預見未來進行合併收



購，則您可以在那時依照本公司開曼群島法令章程召集之股東大會獲得半數股東同意，依相關要約條款出售您的持股。

12. 我可以只轉換部分股數嗎？

否。如您希望參與本次轉換，請依上述美國存託憑證表彰普通股數量(1:5)，將您所持有之本公司股份一次全數轉換。(注意: 未達 5 股之畸零股普通股將不足轉換 1 股美國存託憑證)

13. 公司終止有價證券櫃檯買賣後可能發生哪些會影響股票價值的關鍵事項？

本公司於終止有價證券櫃檯買賣以及停止在台灣有價證券公開發行後，將轉移第一上市市場重心至那斯達克交易所。我們將持續擴大產品組合並聚焦發展及具潛力之 ASLAN004 應用於異位性皮膚炎，並預計於 2020 年第四季發布 ASLAN004 多劑量遞增藥物試驗(MAD)期中數據及概念性試驗數據並於 2021 年展開第 2b 期臨床試驗。這些都是可能影響未來股票價值之關鍵事項。

聯絡資訊

當地執行單位： 群益金鼎證券股份有限公司
電話: +886 2 2702 3999
傳真: +886 2 2706 3300
電子信箱: A33424@capital.com.tw

本公司： 亞獅康股份有限公司
Tel: +65 6222 4235
Fax: +65 6225 2419
電子信箱: sharetransfer@aslanpharma.com

免責聲明

上述轉換辦法暨投資人問答如有不盡之處一切以本公司董事會決議、本公司應適用之法令及本公司章程規定辦理。請參閱本公司官網已取得最新訊息。對於任何未遵循程序之異議股東本公司保留其轉換權且本公司不負擔任何此類未轉換之責任。

關於亞獅康-KY

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEX:6497) — 聚焦於臨床階段腫瘤及免疫學並致力於開發創新療法來改變患者生活之臨床階段生物製藥公司(NASDAQ:ASLN, TPEX:6497)。亞獅康-KY由經驗豐富的管理



團隊及全球製藥專家帶領，旗下的臨床試驗藥品組合包括針對異位性皮膚炎與其它免疫適應症進行開發的同級首見之單株抗體療法ASLAN004，以及一款鎖定腫瘤的小分子抑制劑。亞獅康-KY的合作夥伴包括 Almirall、Array BioPharma、Bristol-Myers Squibb(BMS) 及 CSL。欲獲得更多資訊，請參考 www.aslanpharma.com。

前瞻性聲明

本轉換辦法暨投資人問答係為譯本，相關內容及聲明均以本公司英文版公告為主。本文件及相關資訊包含各項前瞻性陳述。該等陳述係基於本公司管理階層目前之看法及期待。該等前瞻性陳述包括但不限於對本公司正在進行的臨床試驗、本公司之商業策略、本公司發展並商品化候選藥物之計畫、本公司候選藥物之安全性與功效、本公司向主管機關提出申請及核准之計畫與時程、及本公司候選藥物規模及市場成長之可能性的時程、範圍、進行和結果的陳述。該等前瞻性陳述係依據管理階層目前之假設以及對未來事件或趨勢之預估，這些假設及預期亦會受到公司經營、策略、營運、財務績效、先天性已知及未知風險、不確定性所影響。項目實際成果及時程，可能與前瞻性陳述所估計的內容產生重大差異。該等重大差異，係肇因於風險及不確定因素，包括但不限於向美國證券交易委員會提交之申請及報告中所提到之風險因素(證管會檔案編號：001-38475)，該等申請及報告亦包括本公司於2020年4月16日向美國證券交易委員會提交之截至2019年12月31日之年報(20-F)。

除了歷史資訊外，本新聞稿中所有之陳述皆為前瞻性陳述，在某些情形下，您可以藉由特定的字詞，例如「將」、「期待」、「擬」、「計畫」、「目標」、「相信」、「預估」、「潛在」、「繼續」與「發展」，或前述字詞之反義字，或其他用以辨別關於未來之陳述之類似字詞，以判斷前瞻性陳述。本新聞稿中的前瞻性陳述，僅代表本公司於該日之觀點，本公司目前在法律許可之範圍內，並無更新該等前瞻性陳述之義務。



Q&A for Shareholders

Delisting from TPEX and moving primary listing to Nasdaq:

Conversion of TPEX-listed shares to Nasdaq-listed ADS

On 16 July 2020, the Taipei Exchange (TPEX) notified ASLAN Pharmaceuticals Limited (6497:TT) (ASLAN) that it had determined ASLAN no longer met the exchange requirements as set out in Article 12-2 of the Taipei Exchange Rules Governing Securities Trading on the TPEX, and that trading of ASLAN's shares on TPEX would terminate as from 25 August 2020.

Our shares are also publicly traded in the form of American Depositary Shares (ADSs) on the US Nasdaq market. Delisting from TPEX will not affect our US listing which will become our primary listing and our ADSs will continue to trade in the US. Holders of ADSs do not need to take any action.

We would like to help Taiwan shareholders who choose to do so, convert their shares into ADSs so they can be held and/or traded on Nasdaq. Shareholders are under no obligation to convert their shares and may also either sell their shares on TPEX before trading ceases or retain their shares without conversion. Please note, however, that once TPEX trading ceases, the only public market for our securities will be through ADSs.

This document provides guidance on the conversion process and addresses certain questions that shareholders may have.

1. What is an ADS?

An American Depositary Share is a security issued by a depositary bank representing the underlying shares of a foreign corporation, such as ASLAN. In our case, our ADSs are issued by JPMorgan Chase Bank, N.A. (JPMorgan), one of the leading banks in the world, with each ASLAN ADS currently representing five of our ordinary shares (the same class of shares as currently listed on TPEX). Our ADSs currently trade on The Nasdaq Global Market stock exchange (Nasdaq) under the trading symbol "ASLN". Subject to certain exemptions and limitations, listings of ADSs on Nasdaq require generally the same level of compliance and reporting rigour as for US-listed domestic companies, all of which ASLAN has met since its Nasdaq listing in May 2018. ASLAN, by offering its shares on U.S. exchanges via ADS, gains the advantage of a wide and sophisticated investor base, which has particular understanding of biotechnology companies, as well as a highly liquid market for the trading of biotechnology stock.

2. Will I be able to convert my Taiwan shares into ADS?

We believe it would be in shareholders' best interests to convert their shares into ADSs, which historically have traded at a significantly higher price and with higher volumes than our shares on TPEX. This document outlines the conversion plan and process. We can only convert your shares if our public company status is withdrawn, which is at the discretion of the Taiwan Securities & Futures Bureau (SFB). We will be asking for shareholders to vote at a forthcoming EGM scheduled on 4 September 2020 to support the withdrawal of public company status after trading ceases on TPEX, which the SFB will take into account when they decide whether to remove our public company status. If we remain a public company in Taiwan, your shares cannot be converted and cannot be traded on any exchange starting from 25 August 2020.



3. Who can convert their shares to ADS?

Trading of our shares on TPEx will cease starting from 25 August 2020. The last trading day will be on 24 August 2020. All individual shareholders holding shares on the last trading day, 24 August 2020, are eligible to convert their shares to ADS. Each ASLAN ADS currently represents five ordinary shares. Please note the remaining ordinary shares not in multiples of five will not be converted to one ADS. For the avoidance of doubt, shares privately obtained or sold by any shareholders after 24 August 2020, the last trading day, will not be eligible for conversion.

4. When can shareholders convert their shares to ADS?

Trading of our shares on TPEx will cease as from 25 August 2020. Shareholders wishing to convert their shares to ADSs must apply before 25 September 2020. You can download the conversion forms from the Company website or request them from our Local Administrator, CAPITAL Securities ('CAPITAL'), which is based in Taiwan (contact details at end), and start preparing the documents required for conversion (see item 7 below). These forms cannot take effect until after our public company status is withdrawn. We expect this process will take approximately 1 to 2 months.

5. Is there a deadline for applying for conversion?

Applications for share conversion will be processed as from and including 25 August. The deadline for submitting your application for conversion is 25 September. Any applications received after this time may not be processed.

6. What will I need for conversion?

In order to convert, you will need to have a US brokerage account, or a US sub-brokerage arrangement with your local broker. If you do not have a US brokerage account or arrangement you will not be able to convert your shares into ADS.

7. What is the process and what forms are required to convert my ASLAN shares into ADS?

You must first contact your broker to instruct them to transfer electronic records of your non-physical shares from the general account of our company Stock Services Agent, TDCC, to the dedicated account of CAPITAL, account number: 3DP8-555555.

Then please download the documents below from the Company website from 25 July 2020 (<https://ir.aslanpharma.com/shareholder-faqs>, under Investor Relations / Shareholder Services) or email sharetransfer@aslanpharma.com:

- **Instrument of Transfer:**

This is required by the Cayman Registrar and will transfer your shares into the name of JPMorgan Chase Bank N.A., which holds them on trust on your behalf (along with all the other holders of ADSs). Please state the number ordinary shares which are to be converted to ADSs and sign;

- **Letter of Transmittal:**

This form is to request JPMorgan to deliver the ADSs to your broker after the conversion process has been completed. Simply pre-sign and leave all other fields



blank - detailed information regarding the number of shares, share certificate numbers etc will be filled in by the Cayman/Branch Registrar on your behalf before forwarding to JPMorgan.

Once you have completed and signed the above forms please send them to CAPITAL before 25 September 2020. Please note that CAPITAL will only start processing completed forms after cessation of trading, 25 August. You will need to send original, signed copies and we recommend you send them by registered mail to ensure they arrive safely. CAPITAL will then check the forms and forward those to our Cayman Registrar for further processing to enable JPMorgan to issue the ADS. You also need to pay the ADS issuance fee and Administration fee (see point 10 below) to CAPITAL before 25 September in order for transfer request to be processed.

All the above documents and a sample manual will be available on the Company website from 25 July 2020.

8. How long will the conversion process take?

Assuming all the original documents received by JPMorgan are all in order, it typically will take around 1-2 months to convert shares to ADSs and place these into your US trading account. However, the Company cannot guarantee these timelines which are outside its control.

9. When can I trade my ADS on the Nasdaq market?

The US broker or sub-broker will be able to let you know when you will be permitted to trade ADSs, depending on when the ADSs are placed into your account and any other requirements that they might have.

10. What are the estimated costs?

The fees below are payable to third parties for administration and processing fees. There are no fees payable to the Company.

- **ADS Issuance fee:**
Shareholders will be required to pay an issuance fee of 5 US cents (USD 0.05) per ADSs charged by JPMorgan, exclusive of any applicable taxes.
- **Administration fee:**
To cover the third-party fees incurred in processing the conversion, there is a charge of USD 20 per shareholder.

For example, if you hold 1,000 Taiwan shares (equivalent of 200 ADS) and wish to convert these, you will need to pay USD 30.00 to CAPITAL (to the dedicated account referred to above): USD 20 administration fee + USD 0.05 per ADS.

There are other fees you may need to make to third parties (depending on your circumstances). These include:



- **Account Opening fee:**
If you do not have an existing US brokerage / sub-brokerage account to trade in US, there will be some fees for opening the account. For these, check with your broker.
- **Trading Activity fee:**
When you trade ADS, there will be brokerage / sub-brokerage account trading fees. This fee may vary based on the broker used to effect your trades. For the Taiwan sub-brokerage account, the trading activity fee is typically 0.00221% every transaction, with a maximum of USD 5.95 and a minimum of USD 0.01. This may vary from time to time. Please check with your broker for more details.
- **ADS Broker Custodian fee:**
For the Taiwan sub-brokerage account, your local broker will work with different U.S. brokers to manage your ADS from Taiwan. You will also be charged USD 0.01 to USD 0.05 per ADS semi-annually or annually, depending on your local broker.

These costs are based on the most up to date information provided to the Company at the time of writing. However, the Company is unable to guarantee these figures are accurate or complete.

Please contact your tax advisor for advice on any tax issues which may arise from trading of ADSs on the Nasdaq market.

11. What happens if I do not convert my shares?

If you do not intend to convert, you may sell your shares on TPEx before 25 August. After this date, you will no longer be able to trade these shares on TPEx or any other stock exchange. You will, however, still own those ASLAN shares and be eligible to vote and receive dividends, and effect a private sale following Cayman law procedures, but no public market to trade these shares will exist for them. If ASLAN were to be involved in a corporate transaction, for instance if ASLAN was acquired, you would be able to sell your shares at that point (subject to whatever offer terms were made to the Company and accepted by a majority of shareholders).

12. Can I convert some but not all of my shares to ADS?

If you wish to take advantage of the opportunity to convert your shares to ADS, you must convert all your shares at the same time. Each ASLAN ADS currently represents five ordinary shares. Please note the remaining ordinary shares not in multiples of five will not be converted to one ADS.

13. What key events could occur after delisting that could affect the value of the shares?

We continue to advance our portfolio, and are focused on the development of ASLAN004 in atopic dermatitis. We expect to announce interim data from the ongoing MAD / proof-of-concept study in 4Q 2020, and complete the study in the first half of 2021, after which we plan to initiate a phase 2b study. These events may affect the value of our ADS in the future.

**Contact Details:**

Local Administrator: CAPITAL Securities
Tel: +886 2 2702 3999
Fax: +886 2 2706 3300
Email: A33424@capital.com.tw

Company: ASLAN Pharmaceuticals
Tel: +65 6222 4235
Fax: +65 6225 2419
Email: sharetransfer@aslanpharma.com

Disclaimer

The above procedures may be amended from time to time: please check website for the latest. We reserve the right in our sole discretion not to proceed with conversion for any individual shareholder who fails to follow, or disputes any aspect of, the company's procedures for conversion; and we accept no liability for any such non-conversion.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEX:6497) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialization, ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology. ASLAN's partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL. For additional information please visit www.aslanpharma.com.

Forward looking statements

This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the potential delisting of the Company's ordinary shares from TPEX, including the timing of such delisting; the ability of the Company to develop and implement a plan to enable holders of the Company's ordinary shares to convert such securities into ADSs tradeable on Nasdaq; the potential benefits and financing ability of the Company as a result of a potential TPEX delisting or otherwise; and the Company's business strategy, the Company's plans to develop and commercialize its product candidates, the safety and efficacy of the Company's product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company's product candidates. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-



looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company's U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 16, 2020. All statements other than statements of historical fact are forward-looking statements.

All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.